Breaking News

19,740 new cases of COVID-19 reported in India; Active caseload lowest in 206 days

19,740 new recorded in India coronavirus Cases in the last 24 hours, ending at 8 am on Saturday. The Ministry of Health and Family Welfare said the active caseload in the country has come down to 2.36 lakh (2,36,643), the lowest in 206 days.

With 284 deaths due to the deadly infection, the death toll has crossed 4.5 lakh.

Kerala continues to be the largest contributor to the national caseload adding 10,944 fresh cases. With 120 new deaths, the state is also reporting the highest number of daily Covid deaths.

Kerala to add 7,000 Covid-19 deaths; Toll 33,000. touched on

Amid criticism for allegedly under-reporting, the Kerala government has decided to add 7,000 deaths to the death toll in the states. In addition the state will take COVID-19 The death toll rose by 26,000 to 33,000 on Saturday.

Announcing the decision, state Health Minister Veena George said 7,000 cases were not recorded in the official figures in the absence of relevant records. “If there are complaints about omissions in the list, the health department is ready to look into them,” she said.

Almost all residents of Gautam Buddh Nagar have been given at least one shot of COVID-19 vaccine: Official

Officials said that almost every eligible beneficiary has been given at least one dose of the Kovid vaccine in Delhi’s Gautam Buddh Nagar. Now the focus is to vaccinate about 12,000 beneficiaries in the remaining 45+ age group.

Last week the health department launched a special drive to provide the first dose to people in this age group.

Two Indian drugmakers to end trial of generic Merck pill to moderate Covid-19

Two Indian drugmakers, Aurobindo Pharma Ltd and MSN Laboratories, have requested permission to conclude late-stage trials of their generic versions of Molnupiravir, a promising experimental oral antiviral drug from Merck & Co for the treatment of moderate cases of Covid-19. It comes a week after Merck said its own trial had been successful for mild to moderate patients.


According to a Merck spokesperson, Merck and the Indian companies had defined “moderate” disease differently. Merck’s tests are based on US Food and Drug Administration definitions, which give blood oxygen levels of no less than 93 percent for moderate COVID-19.

Back to top button